c
2
12
18
28
12
12
1a
14
e
12
16
a
a
2
2
a
20
32
1a
2a
19
Faculty
61 16
19
1
49
2
2
1a
32
34
1b
1d
18
3c
47
1d
2 29
1d
25
Todd William Ridky, M.D.,Ph.D.
78
47
Associate Professor of Dermatology
7
62
Department: Dermatology
4
1
23
1f
Graduate Group Affiliations
8
a
b
1d
46
Contact information
47
4
3
3
1d
47
Department of Dermatology
22 University of Pennsylvania
29 1010 Biomedical Research Building
31 421 Curie Blvd
Philadelphia, PA 19104
26
22 University of Pennsylvania
29 1010 Biomedical Research Building
31 421 Curie Blvd
Philadelphia, PA 19104
2e
Office: 215 573 5709
30
f
30
18
Publications
23 a
3
2
4
b
1f
23 a
13
Education:
21 9 B.S. 16 (Chemistry) c
44 University of North Carolina at Chapel Hill, 1992.
21 a Ph.D. 19 (Biochemistry) c
38 Case Western Reserve University, 1997.
21 9 M.D. c
4b Case Western Reserve University School of Medicine, 1999.
21 a Cert. 58 (Research Mentor Training: Effective Communication and Aligning Expectations) c
33 University of Pennsylvania, 2022.
c
3
27
21 9 B.S. 16 (Chemistry) c
44 University of North Carolina at Chapel Hill, 1992.
21 a Ph.D. 19 (Biochemistry) c
38 Case Western Reserve University, 1997.
21 9 M.D. c
4b Case Western Reserve University School of Medicine, 1999.
21 a Cert. 58 (Research Mentor Training: Effective Communication and Aligning Expectations) c
33 University of Pennsylvania, 2022.
c
Links
a0 Search PubMed for articles
60 Ridky Lab Web Page
65 Society for Investigative Dermatology
66 American Association for Cancer Research
c
5
3
3
92
Permanent linka0 Search PubMed for articles
60 Ridky Lab Web Page
65 Society for Investigative Dermatology
66 American Association for Cancer Research
c
2 29
21
1e
1d
24
5e
71
38 Gene regulatory control of epidermal homeostasis
1e Epithelial oncogenesis
29 Tissue models of human malignancy
8
20 Description of Research:
8a8 The Ridky Lab uses genetically-defined, engineered epithelial tissues as an experimental platform to study pathways driving human cancer initiation, stromal invasion, tumor-stroma interaction, metastasis, and maintenance of cancer stem cells. Tissue models of invasive malignancy are used to identify and validate new targets for potential therapeutics. To maximize the physiologic and medical relevance of our efforts, we develop experimental human tissue systems based on normal primary human cells established within an architecturally faithful native 3-D environment incorporating intact mesenchymal stroma and living stromal cells. Progression to cancer is driven by genetic changes initially identified in spontaneous tumors in humans and specifically engineered into the model tissues. Many experiments are conducted entirely in this organotypic environment, while in vivo studies utilize immunodeficient mice as hosts for the engineered tissues. These new models allow up to 10 alleles or more to be altered simultaneously in 1-2 days, permitting genetic experiments with an unprecedented degree of rapidity and complexity exceeding that previously possible in traditional genetic experimental organisms, such as transgenic mice. These new genetic models, which we refer to as "Multifunctional Human Tissue Genetics", have allowed us to directly convert multiple normal human tissues into invasive cancer via targeted, specific alterations in defined, medically-relevant genetic networks. Bioinformatics-intensive systems biology approaches are used to identify centrally-acting elements that are likely important for promoting cancer progression. To determine functional roles for specific tumor cell or stromal cell-intrinsic factors, we employ various genetic and protein level interventions, including multiplexed expression of tumor-associated mutant oncogenic drivers, tumor suppressors, and conditionally active proteins. Disruption of primary oncogenic signaling and non-oncogene addicted (NOA) pathways is achieved via RNA interference (RNAi), as well as chemical small molecule inhibitors and protein based biologic agents as a foundation for development of targeted molecular therapeutics.
8
16 Lab Personnel:
2b Andrew McNeal - Research Specialist
25 Emily Schapira - UPenn (2013)
20 Kevin Liu - UPenn (2013)
25 Vihang Nakhate - UPenn (2014)
29 Seung Ja Oh - Postdoctoral fellow
8
15 Lab Web Page:
29 http://www.med.upenn.edu/ridkylab/
e 29
27
Description of Clinical Expertise
23 General Dermatology71
Description of Research Expertise
23 Epithelial biology38 Gene regulatory control of epidermal homeostasis
1e Epithelial oncogenesis
29 Tissue models of human malignancy
8
20 Description of Research:
8a8 The Ridky Lab uses genetically-defined, engineered epithelial tissues as an experimental platform to study pathways driving human cancer initiation, stromal invasion, tumor-stroma interaction, metastasis, and maintenance of cancer stem cells. Tissue models of invasive malignancy are used to identify and validate new targets for potential therapeutics. To maximize the physiologic and medical relevance of our efforts, we develop experimental human tissue systems based on normal primary human cells established within an architecturally faithful native 3-D environment incorporating intact mesenchymal stroma and living stromal cells. Progression to cancer is driven by genetic changes initially identified in spontaneous tumors in humans and specifically engineered into the model tissues. Many experiments are conducted entirely in this organotypic environment, while in vivo studies utilize immunodeficient mice as hosts for the engineered tissues. These new models allow up to 10 alleles or more to be altered simultaneously in 1-2 days, permitting genetic experiments with an unprecedented degree of rapidity and complexity exceeding that previously possible in traditional genetic experimental organisms, such as transgenic mice. These new genetic models, which we refer to as "Multifunctional Human Tissue Genetics", have allowed us to directly convert multiple normal human tissues into invasive cancer via targeted, specific alterations in defined, medically-relevant genetic networks. Bioinformatics-intensive systems biology approaches are used to identify centrally-acting elements that are likely important for promoting cancer progression. To determine functional roles for specific tumor cell or stromal cell-intrinsic factors, we employ various genetic and protein level interventions, including multiplexed expression of tumor-associated mutant oncogenic drivers, tumor suppressors, and conditionally active proteins. Disruption of primary oncogenic signaling and non-oncogene addicted (NOA) pathways is achieved via RNA interference (RNAi), as well as chemical small molecule inhibitors and protein based biologic agents as a foundation for development of targeted molecular therapeutics.
8
16 Lab Personnel:
2b Andrew McNeal - Research Specialist
25 Emily Schapira - UPenn (2013)
20 Kevin Liu - UPenn (2013)
25 Vihang Nakhate - UPenn (2014)
29 Seung Ja Oh - Postdoctoral fellow
8
15 Lab Web Page:
29 http://www.med.upenn.edu/ridkylab/
e 29
23
fa Marinaro C, Sauer J, Natale CA, Ridky T, Chen S.: An In Vivo Study of LNS8801, a GPER Agonist, in a Spontaneous Melanoma-Prone Mouse Model, TGS. Pigment Cell Melanoma Res 2025.
182 Lee I, Doepner M, Weissenrieder J, Majer AD, Mercado S, Estell A, Natale CA, Sung PJ, Foskett JK, Carroll MP, Ridky TW.: LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway. Cancer Res Commun 3: 1594-1606, Aug 2023.
e4 Hatterschide J, Natale CA, Ridky TW, White EA.: Monitoring cell fate in 3D organotypic human squamous epithelial cultures. STAR Protoc 4: 102101, Mar 2023.
11e Kohli J, Ge C, Fitsiou E, Doepner M, Brandenburg SM, Faller WJ, Ridky TW, Demaria M.: Targeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regression. Nat Commun 13: 7923, Dec 2022.
14a Doepner M, Lee I, Natale CA, Brathwaite R, Venkat S, Kim SH, Wei Y, Vakoc CR, Capell BC, Katzenellenbogen JA, Katzenellenbogen BS, Feigin ME, Ridky TW.: Endogenous DOPA inhibits melanoma through suppression of CHRM1 signaling. Sci Adv 8: eabn4007, Sep 2022.
102 Aguirre-Portolés C, Payne R, Trautz A, Foskett JK, Natale CA, Seykora JT, Ridky TW.: ZIP9 Is a Druggable Determinant of Sex Differences in Melanoma. Cancer Res 81: 5991-6003, Dec 2021.
9c Pharmacologic activation of the G protein-coupled estrogen receptor inhibits pancreatic ductal adenocarcinoma 79 Christopher A. Natale, Jinyang Li, Tzvete Dentchev, Brian C. Capell, John T. Seykora, Ben Z. Stanger, Todd W. Ridky 78 : Pharmacologic activation of the G protein-coupled estrogen receptor inhibits pancreatic ductal adenocarcinoma 3d Cellular and Molecular Gastroenterology and Hepatology 2b 2020 Notes: in press.
159 Monteleon Christine L, Lee In Young, Ridky Todd W: Exophilin-5 supports lysosome-mediated trafficking required for epidermal differentiation. The Journal of investigative dermatology 139(10): 2219-2222.e6, Oct 2019 Notes: doi: 10.1016/j.jid.2019.04.014. Epub 2019 May 11.
251 Lee Vivian, Gober Michael D, Bashir Hasan, O'Day Conor, Blair Ian A, Mesaros Clementina, Weng Liwei, Huang Andrew, Chen Aaron, Tang Rachel, Anagnos Vince, Li JiLon, Roling Sophie, Sagaityte Emilija, Wang Andrew, Lin Chenyan, Yeh Christopher, Atillasoy Cem, Marshall Christine, Dentchev Tzvete, Ridky Todd, Seykora John T: Voriconazole enhances UV-induced DNA damage by inhibiting catalase and promoting oxidative stress. Experimental dermatology 29(1): 29-38, Sep 2019 Notes: doi: 10.1111/exd.14038 [Epub ahead of print]
2c
7
1d
1f
Selected Publications
154 Natale CA, Mercado S, Zhuang R, Aguirre-Portolés C, Olayide I, Arnatt CK, Seykora JT, Garyantes TK, Luke W, Ridky TW.: LNS8801: An enantiomerically pure agonist of the G protein-coupled estrogen receptor suitable for clinical development. Cancer Res Commun Mar 2025.fa Marinaro C, Sauer J, Natale CA, Ridky T, Chen S.: An In Vivo Study of LNS8801, a GPER Agonist, in a Spontaneous Melanoma-Prone Mouse Model, TGS. Pigment Cell Melanoma Res 2025.
182 Lee I, Doepner M, Weissenrieder J, Majer AD, Mercado S, Estell A, Natale CA, Sung PJ, Foskett JK, Carroll MP, Ridky TW.: LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway. Cancer Res Commun 3: 1594-1606, Aug 2023.
e4 Hatterschide J, Natale CA, Ridky TW, White EA.: Monitoring cell fate in 3D organotypic human squamous epithelial cultures. STAR Protoc 4: 102101, Mar 2023.
11e Kohli J, Ge C, Fitsiou E, Doepner M, Brandenburg SM, Faller WJ, Ridky TW, Demaria M.: Targeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regression. Nat Commun 13: 7923, Dec 2022.
14a Doepner M, Lee I, Natale CA, Brathwaite R, Venkat S, Kim SH, Wei Y, Vakoc CR, Capell BC, Katzenellenbogen JA, Katzenellenbogen BS, Feigin ME, Ridky TW.: Endogenous DOPA inhibits melanoma through suppression of CHRM1 signaling. Sci Adv 8: eabn4007, Sep 2022.
102 Aguirre-Portolés C, Payne R, Trautz A, Foskett JK, Natale CA, Seykora JT, Ridky TW.: ZIP9 Is a Druggable Determinant of Sex Differences in Melanoma. Cancer Res 81: 5991-6003, Dec 2021.
9c Pharmacologic activation of the G protein-coupled estrogen receptor inhibits pancreatic ductal adenocarcinoma 79 Christopher A. Natale, Jinyang Li, Tzvete Dentchev, Brian C. Capell, John T. Seykora, Ben Z. Stanger, Todd W. Ridky 78 : Pharmacologic activation of the G protein-coupled estrogen receptor inhibits pancreatic ductal adenocarcinoma 3d Cellular and Molecular Gastroenterology and Hepatology 2b 2020 Notes: in press.
159 Monteleon Christine L, Lee In Young, Ridky Todd W: Exophilin-5 supports lysosome-mediated trafficking required for epidermal differentiation. The Journal of investigative dermatology 139(10): 2219-2222.e6, Oct 2019 Notes: doi: 10.1016/j.jid.2019.04.014. Epub 2019 May 11.
251 Lee Vivian, Gober Michael D, Bashir Hasan, O'Day Conor, Blair Ian A, Mesaros Clementina, Weng Liwei, Huang Andrew, Chen Aaron, Tang Rachel, Anagnos Vince, Li JiLon, Roling Sophie, Sagaityte Emilija, Wang Andrew, Lin Chenyan, Yeh Christopher, Atillasoy Cem, Marshall Christine, Dentchev Tzvete, Ridky Todd, Seykora John T: Voriconazole enhances UV-induced DNA damage by inhibiting catalase and promoting oxidative stress. Experimental dermatology 29(1): 29-38, Sep 2019 Notes: doi: 10.1111/exd.14038 [Epub ahead of print]
2c
4d
22
22
7
10
a
a
2
2
19
18
10
22
10
11
c
5b © The Trustees of the University of Pennsylvania | Site best viewed a in a supported browser. | Site Design: 57 PMACS Web Team. 3 22
10